Jason Jardine, Makoto Tsunozaki Ph.D. On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO ...
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on ...
Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
Incyte has expanded its graft-versus-host disease (GVHD) offerings beyond Jakafi. The new addition comes from axatilimab, a CSF-1R inhibitor partnered with Syndax Pharmaceuticals. Wednesday, the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback